● Recruiting

This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.

Condition: Relapsed/Refractory Small Cell Lung Cancer · Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

PhasePhase 1

Planned participants55

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersYes

About this study

This is a First-in-Human, open-label, early dose-escalation clinical study to evaluate the safety and preliminary efficacy of GC511B CAR T cell injection in Adult with DLL3+ r/r SCLC trial participants.

This description comes directly from the study's public registry record.

Talk to the study team

Ning Li, Ph.D. · +86 15601395554 · lining@cicams.ac.cn

Always discuss trial participation with your own doctor first.

Locations (2)

Cancer Hospital, Chinese Academy of Medical Sciences	Beijing, Beijing Municipality, China	Recruiting
Beijing Gobroad Hospital	Beijing, Beijing Municipality, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07249879